Mukhtar, R. A., Dimitroff, K., Yau, C., Chien, A. J., Connolly, E. P., Howard-McNatt, M., Rao, R., Ladores, V., Golshan, M., Sauder, C. A., Ahmed, K., Lancaster, R., Fox, J., Gutnik, L., Lee, M. C., Tchou, J., Prionas, N., Arciero, C. A., Reyna, C., Kuerer, H., Switalla, K., Taunk, N., Tuttle, T. M., Moran, M. S., Postlewait, L. M., Perlmutter, J., DeMichele, A., Yee, D., Hylton, N., Symmans, W. F., Rugo, H. S., Shatsky, R., Isaacs, C., Esserman, L. J., Van't Veer, L., Boughey, J. C. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial , Annals of surgical oncology: 2025

Villacampa, G., Pascual, T., Tarantino, P., Cortés, J., Perez-García, J., Llombart-Cussac, A., Conte, P., Mancino, M., Guarneri, V., Dieci, M. V., Waks, A. G., Schettini, F., Brasó-Maristany, F., Griguolo, G., de Castro, B. A., Reboredo, C., Antolín, S., Bueno-Muiño, C., Echavarría, I., López-Tarruella, S., Massarrah, T., Monte-Millán, M. D., Martin, M., Buckingham, W., Parker, J. S., Vivancos, A., Polyak, K., Filho, O. M., Wolff, A. C., DeMichele, A., Tung, N. M., Perou, C. M., Paré, L., Villagrasa, P., Prat, A., Tolaney, S. M. HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis , Lancet Oncology: 2025

Kaur, M., Dimitroff, K., Boughey, J. C., Esserman, L. J., Yau, C., Tchou, J., Quirarte, A., Lee, M. C., Howard-McNatt, M. M., Switalla, K., Kuerer, H., Sauder, C., Postlewait, L. M., Arciero, C., Rao, R., Wallace, A., Reyna, C., Ahmed, K., Gutnik, L., Taunk, N., Perlmutter, J., DeMichele, A., Yee, D., Yee, D., Hylton, N., Symmans, W. F., Rugo, H. S., Shatsky, R., Isaacs, C., Rudra, S., Pohlmann, P., Ewing, C., Wong, J., Alvarado, M., Jaskowiak, N., Prionas, N., Golshan, M., Piltin, M. A., Olopade, O. I., Mukhtar, R. A. Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial , Annals of surgical oncology: 2025

Shinn, E., Zahrieh, D., DeMichele, A., Zdenkowski, N., Lemieux, J., Mao, J., Bjelic-Radisic, V., Naughton, M. J., Pfeiler, G., Gelmon, K., Balko, J. M., Egle, D., Zoppoli, G., Traina, T., Jimenez, M. M., Novoa, S. A., Haddad, T., Chan, A., Ring, A., Wolff, A., Symanns, W. F., Lorenzo, J. P., Sabanatha, D., Burstein. H. J., Bellet-Ezquerra, M., Foukakis, T., Novik, Y., Rubovszky, G., Singer, C. F., Muehlbacher, K., Filho, O. M., Goulioti, T., Law, E., Partridge, A. H., Carey, L. A., Zoroufy, A., Hlauschek, D., Fesl, C., Mayer, E. L., Gnant, M. Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer , Breast Cancer Res Treat: 2025

Wolf, D. M., Yau, C., Campbell, M., Glas, A., Barcaru, A., Mittempergher, L., Kuilman, M., Brown-Swigart, L., Hirst, G., Basu, A., Magbanua, M., Sayaman, R., Huppert, L., Delson, A., I-SPY2 Investigators, Symmans, W. F., Borowsky, A., Pohlmann, P., Rugo, H., Clark, A., Yee, D., DeMichele, A., Perlmutter, J., Petricoin, E. F., Chein, J., Stringer-Reasor, E., Shatsky, R., Liu, M., Han, H., Soliman, H., Isaacs, C., Nanda, R., Hylton, N., Pusztai, L., Esserman, L., van 't Veer, L. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial , JCO Precis Oncol: 2025

Hahnen, E., Hauke, J., Gelmon, K., Marmé, F., Ernst, C., Martin, M., Untch, M., Bonnefoi, H., Knudsen, E., Im, S.-A., DeMichele, A., Van’t Veer, L., Kim, S.-B., Bear, H., McCarthy, N., Rhiem, K., Turner, N., Witkiewicz, A., Rojo, F., Filipits, M., Martin, LA., Fasching, P. A., Schem, C., Becker, K., García-Sáenz, J. A., Kelly, C. M., Reimer, T., Toi, M., Rugo, H. S., Denkert, C., Gnant, M., Makris, A., Liu, Y., Valota, O., Felder, B., Weber, K., Nekljudova, V., Loibl, S. BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis , JCO Precision Oncology: 2025

Thomas, A., Mayer, E. L., DeMichele, A., Harbeck, N., Curigliano, G., Ignatiadis, M., Adam, V., Zhou, Y., Brown, T. P., Gilham, L., Chua, B. H., Kalinsky, K., Wolff, A. C., & O'Reilly, S. Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast Cancer , J Clin Oncol: 2025

Huppert, L. A., Wolf, D., Yau, C., Brown-Swigart, L., Hirst, G. L., Isaacs, C., Pusztai, L., Pohlmann, P. R., DeMichele, A., Shatsky, R., Yee, D., Thomas, A., Nanda, R., Perlmutter, J., Heditsian, D., Hylton, N., Symmans, F., Van't Veer, L. J., Esserman, L., & Rugo, H. S. Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial , Annals of Oncology: 2025

Li, W., Onishi, N., Gibbs, J. E., Wilmes, L. J., Le, N. N., Metanat, P., Price, E. R., Joe, B. N., Kornak, J., Yau, C., Wolf, D. M., Magbanua, M. J. M., LeStage, B., van 't Veer, L. J., DeMichele, A. M., Esserman, L. J., & Hylton, N. M. MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer , Tomography: 2025

Mukhtar, R. A., Gottipati, S., Yau, C., López-Tarruella, S., Earl, H., Hayward, L., Hiller, L., Osdoit, M., van der Noordaa, M., de Croze, D., Hamy, A. S., Laé, M., Reyal, F., Sonke, G. S., Steenbruggen, T. G., van Seijen, M., Wesseling, J., Martín, M., Del Monte-Millán, M., Boughey, J. C., Goetz, M. P., Hoskin, T., Valero, V. Edge, S. B., Abraham, J. E., Bartlett, J. M. S., Caldas, C., Dunn, J., Provenzano, E., Sammut, S. J., Thomas, J. S., Graham, A., Hall, P., Mackintosh, L., Fan, F., Godwin, A. K., Schwensen, K., Sharma, P., DeMichele, A. M., Cole, K., Pusztai, L., Kim, M., van 't Veer, L. J., Cameron, D., Laura J Esserman, L. J., Fraser Symmans, W. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer , NPJ Breast Cancer: 2025